Rivastigmine Tartrate (ENA 713, SDZ-ENA 713, ENA713)，又称酒石酸卡巴拉汀、利斯的明酒石酸盐、卡巴拉汀酒石酸盐、酒石酸利伐斯的明或酒石酸利凡斯的明，是一种可口服的胆碱酯酶抑制剂，IC₅₀为5.5 μM，通过抑制胆碱能神经元对乙酰胆碱的降解而促进胆碱能神经传导，进而促进认知功能，临床上用于治疗阿尔茨海默病。

参考文献

1.Qian-Sheng Yu, et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. J Med Chem. 2002 Aug 15;45(17):3684-91.

2.Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

3.Helena Shifrin, et al. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8(2):e57668.

4.Raafat A Abdel-Aal, et al. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011 Jun 1;659(2-3):169-76.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。